Navigation Links
Orphan Drug Market to Reach $112 Billion in 2017: Bcc Research
Date:7/16/2013

Wellesley, MA (PRWEB) July 16, 2013

In the new report, GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038D), from BCC Research (http://www.bccresearch.com), the global market for orphan drugs was valued at $82.6 billion in 2011 and nearly $86 billion in 2012. The report forecasts total market value to reach $112 billion in 2017, after increasing at a five-year compound annual growth rate (CAGR) of 5.4%.

Orphan drugs are drugs that treat orphan diseases. An orphan disease is a disease that does not receive significant investment, research, or attention from the medical and pharmaceutical industries. Orphan diseases are most often rare diseases and are defined by using a ratio of incidence to population in the U.S., the EU, Japan and other developed countries. An orphan disease can also be a tropical disease whose typical sufferers cannot afford access to pharmaceutical treatment options.

Orphan diseases did not receive much attention from the pharmaceutical industry until the U.S. passed the first Orphan Drug Act in 1983. Other countries quickly began following suit with versions of the Orphan Drug Act. Before governments began passing these acts, the pharmaceutical industry could not make a profit from orphan drugs because of the small market size. Government intervention opened a path to profitability for pharmaceutical companies and created an interest to develop orphan drugs.

BCC Research’s Report analyzes the market for orphan drugs by region, by biological and non-biological drug type, by active ingredient, and by area of medical application. The report reveals why orphan drugs for oncology are the largest category for both biological and non-biological drugs. The report includes a detailed analysis of all other categories within biological and non-biological drugs.

This BCC Research report also provides a detailed explanation of the current market value, forecast, and growth rate for the next five years for both the biological and non-biological orphan drug segments. BCC Research valued the biological orphan drug segment at $57.7 billion in 2012, and expects the value to reach nearly $71.4 billion in 2017, registering a CAGR (compound annual growth rate) of 4.3%. The report valued non-biological orphan drugs at $28.3 billion in 2012, and forecasts the market to reach $40.8 billion in 2017, after growing at a CAGR (compound annual growth rate) of 7.5%.

Some of the growth drivers for the orphan drugs market discussed by BCC Research in the report include increased research and development, new technology, additional regulatory easing, and new product launches. Additionally, the ability of pharmaceutical companies to use orphan drugs for off-label uses is also helping in achieving market growth.

This BCC Research report provides insights into the regulations and laws that are allowing the orphan drugs market to grow. BCC Research’s report provides clear and precise guidance on every aspect of the industry.

The study will be beneficial to pharmaceutical and biotechnical companies, research institutes, and physicians.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10923141.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Ground Broken For New Orphanage In Africa Thanks To Living Fuel And FreeRide836 Kiteboarders
2. Tellurex Sends tPOD1™ to Light Up Orphanage in Uganda
3. FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa
4. 30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease, Pulmonary Hypertension Association Says
5. First Pathfinder Awards announced tackling rare and orphan diseases
6. Clinical Next Generation Sequencing Market: NGS Diagnostic 2018 Forecast in New Industry Research Report at ReportsnReports.com
7. Breast Pumps Market Is Expected to Reach USD 1.03 Billion Globally in 2018 : Transparency Market Research
8. Modular Data Center Market Is Expected to Reach $40.41 Billion by 2018 at a CAGR of 37.41% From 2013 to 2018 - New Report by MarketsandMarkets
9. SevenPoint2, the Alkaline Company, Is Finding a Marketing ‘Balance’ with CallFire’s Tele-pH-ony Solutions
10. Marshall Fong Joins FMC BioPolymer as Global Marketing Director of Food Ingredients
11. Pre-Harvest Market to Reach $55,696.6 Million by 2018 at a CAGR of 5.7% - New Report by MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... emergency and now estimates that there could be four million Zika-related cases in the ... to date with numbers of US cases reported per year skyrocketing to an estimated ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... BELLEVUE, Wash. , March 23, 2017 /PRNewswire/ ... enterprise contract management in the cloud, today ... Agreement and Budgeting solution designed to improve clinical ... Contract Management (ICM) platform , the solution speeds ... compliance with contract research organizations (CRO). ...
(Date:3/23/2017)... March 23, 2017 A research report ... is expected to reach USD 7.2 billion by the end ... preparation is a procedure in which a sample is preserved ... most analytical procedures since the methods are often allowing repeated ... of the most shared procedures in the lab. In many ...
(Date:3/23/2017)... -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company ... unmet medical needs in rare diseases, today announced that ... on Monday, April 3 during ENDO 2017, the annual ... Florida , to discuss new data regarding its ... PTH and TransCon CNP). Ascendis is presenting ...
Breaking Medicine Technology: